Gilberto de Lima Lopes Jr., MD, MBA, FAMS
Medical Director for International Programs and Associate Director for Global Oncology, Sylvester Comprehensive Cancer Center; Associate Professor, University of Miami Miller School of MedicineDr. Gilberto Lopes, an expert in medical oncology in low- and middle-income countries, is Medical Director for International Programs and Associate Director for Global Oncology at the Sylvester Comprehensive Cancer Center and Associate Professor at the University of Miami Miller School of Medicine. He is an associate editor for ASCO University and for ASCO’s Journal of Global Oncology. From 2006 to 2013, Dr. Lopes worked for the Johns Hopkins University Singapore International Medical Center, and, prior to that, was the Chief Medical and Scientific Officer for the Oncoclinicas Group, the largest oncology provider in Latin America with 35 clinics and more than 300 oncologists in nine states in Brazil.
Dr. Lopes has published widely, with more than 100 papers in journals such as the Journal of Clinical Oncology, Cancer, The Lancet, The Lancet Oncology, and Nature Reviews, and has lectured nationally and internationally. He has been principal or co-principal investigator or steering committee member in more than 100 studies and clinical trials covering breast, gastrointestinal, genitourinary, and thoracic cancers. His areas of research interest extend to health economics, value, policy, and access to cancer drugs and treatment in low- and middle-income countries. He has served as an expert for the International Atomic Energy Agency, the World Health Organization and the Pan-American Health Organization.
After graduating from medical school in Brazil, Dr. Lopes received residency training in internal medicine and completed a fellowship in hematology/oncology at the University of Miami.
Disclosures
Honoraria
Company: AstraZeneca
Company: Roche/Genentech
Company: Merck Serono
Company: Merck Sharp & Dohme
Company: Fresenius Kabi
Company: Novartis
Company: Bristol-Myers Squibb
Company: Janssen-Cilag
Company: Boehringer Ingelheim
Company: Pfizer
Company: CIPLA
Company: Sanofi
Company: Eisai
Company: Lilly
Consulting or Advisory Role
Company: Pfizer
Company: Bristol-Myers Squibb
Company: Lilly/ImClone
Research Funding
Company: Lilly/ImClone
Company: Pfizer
Company: AstraZeneca
Company: Merck Sharp & Dohme
Company: Eisai
Company: Bristol-Myers Squibb
Expert Testimony
Company: Sanofi
Recent Contributions to PracticeUpdate:
- Global Challenges in Lung Cancer
- Comparative Effectiveness of Checkpoint Inhibitors in Lung Cancer
- ASCO 2018: Predicting Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PDL-1 Inhibitors
- ASCO 2018: New Phase 3 Data on PD-L1 vs Chemotherapy for First-Line NSCLC
- Impact of Geographic Distribution on Outcome in Cancer: Africa and Asia
- Genitourinary Highlights With Dr. Gilberto Lopes and Dr. Sumanta Pal—PracticeUpdate's ESMO 2016 Coverage